This study demonstrates that integrating two independent RNA-seq analytical workflows enables the identification of robust and clinically meaningful gene signatures in breast cancer, and provides a systematic approach for prioritizing candidate biomarkers and therapeutic targets in cancer transcriptomics.
Abstract
Background Breast cancer is a molecularly heterogeneous disease characterized by diverse transcriptional programs across tumor subtypes. RNA sequencing (RNA-seq) has become a central tool for profiling these alterations; however, variability in data processing pipelines can introduce inconsistencies in downstream analyses, limiting the identification of robust and reproducible gene signatures. Methods We implemented a three-phase integrative framework to identify high-confidence gene signatures in breast cancer. The framework comprised: (i) a discovery phase involving differential expression analysis across two independent RNA-seq workflows — a STAR-counts pipeline applied to a balanced TCGA-BRCA cohort (30 tumor vs. 30 normal samples) processed via TCGAbiolinks, and a Salmon-based pseudo-alignment pipeline applied to an independent SRA-derived dataset (3 tumor vs. 3 normal samples) processed from raw sequencing reads; (ii) a cross-dataset concordance phase identifying consensus upregulated genes through gene symbol intersection analysis; and (iii) a validation and clinical characterisation phase comprising large-scale validation in the full TCGA-BRCA cohort (n□=□1,093 tumors, 112 normal samples), functional enrichment, PAM50 subtype stratification, survival analysis, and cancer cell line expression profiling. A multi-criteria scoring framework was applied to prioritize potential drug targets. Results A total of 666 genes were consistently upregulated across both discovery datasets, indicating strong cross-platform concordance. Of these, 502 genes (93%) were validated as upregulated in the full TCGA cohort, demonstrating high reproducibility. Functional enrichment analyses revealed dominant involvement in cell cycle regulation, chromosomal segregation, and DNA repair pathways. Subtype analysis showed a marked enrichment of these genes in Basal-like and HER2-enriched tumors, highlighting their association with more aggressive disease phenotypes. Survival analysis identified a subset of genes significantly associated with poor overall survival, while cell line validation confirmed expression in breast cancer models. Integration of these features enabled the prioritization of candidate genes with potential therapeutic relevance. Conclusion This study demonstrates that integrating two independent RNA-seq analytical workflows (a STAR-counts pipeline applied to a balanced TCGA-BRCA discovery cohort and a Salmon-based pipeline applied to an independent SRA-derived dataset) enables the identification of robust and clinically meaningful gene signatures in breast cancer. The high concordance observed across these independent datasets underscores the reproducibility of the identified signals, while downstream analyses highlight their biological and translational relevance. This framework provides a systematic approach for prioritizing candidate biomarkers and therapeutic targets in cancer transcriptomics.
Breast cancer is the most commonly diagnosed cancer among women and remains a leading cause of cancer-related mortality. Accurate classification into molecular subtypes—Luminal A, Luminal B, HER2-enriched, and Basal-like—is important because these subtypes differ in biology, prognosis, and treatment response. However,...
Anusha Lakshmi Chintalapati· Proceedings of the OJSS Virt...· 0 citations
Spatial transcriptomics has identified AIF1, LIF, MRC1, and TNC as enriched in tumor-budding (TB) regions of colorectal cancer. We investigated whether this TB-associated gene module could be detected in bulk transcriptomic data. Pairwise gene co-occurrence was analyzed in bulk RNA-seq (TCGA-COADREAD, n=547) and single...
Pritom Sarkar, Pritom Sarkar· bioRxiv· 0 citations
Background/Objectives: Reference genome choice can introduce systematic bias into cancer transcriptomic analyses, particularly for populations underrepresented in standard references. However, its impact on downstream biological interpretation remains insufficiently characterized. Methods: We compared GRCh38, T2T-CHM13...
Esophageal Squamous Cell Carcinoma (ESCC) is an aggressive gastrointestinal malignancy with unfavorable clinical outcomes, and current molecular biomarkers offer limited clinical utility for early detection and precise risk stratification. In this study, we integrated multi-cohort transcriptomic profiling with systems-...
E. Pavithra, K. R. Unni, Febby Payva et al.· Computational biology and ch...· 0 citations
Background/Objectives: Colorectal cancer (CRC) is a leading cause of neoplasia-related morbidity and mortality worldwide and the first cause of cancer death in Mexico, where early detection remains a challenge, and reliable molecular biomarkers could support earlier diagnosis. Transcriptomic signatures for CRC have bee...
César de Jesús Tovar-Jácome, L. F. Jave-Suárez, Jesús García-Gómez et al.· Genes· 0 citations
Reference genome and transcriptome are fundamental components of RNA-seq analysis and can influence transcript quantification and downstream differential expression results. Although GRCh38 is the current human reference build, GRCh37 remains in use in research and clinical bioinformatics workflows. The extent to which...
Paweł Zieliński, M. Frąszczak, Bartosz Czech et al.· International Journal of Mol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.